Stemedica Cell Technologies, Inc. Secures U.S. Patent To Use Multiple Stem Cell Lines Simultaneously To Treat Ischemic Stroke

SAN DIEGO--(BUSINESS WIRE)--Stemedica Cell Technologies, Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, was issued a new patent from the U.S. Patent & Trademark Office (USPTO), US 8,790,638 entitled “Composition of Stem Cells and Stem Cell Factors for Their Use and Manufacture.” This patent covers a method for treating patients with ischemic stroke, and the treatment includes intrathecal administration of hypoxically grown neural stem cells and intravenous administration of hypoxically grown mesenchymal stem cells.

Help employers find you! Check out all the jobs and post your resume.

Back to news